Top stories from TTO's November newsletter:
miRagen Therapeutics Signs Research and Licensing Agreements with CU for microRNA Profiling of Human Heart Failure Study
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and the University of Colorado (CU) announced in late October that they have entered into sponsored research and licensing agreements to collaborate on miRNA therapeutics discovery and development. The sponsored research agreement will support the analysis of miRNA and gene expression changes from a study conducted at the University of Colorado Cardiovascular Institute at the UC Denver School of Medicine, "Beta Blocker Effects on Remodeling and Gene Expression (BORG)," while the licensing agreement will enable the company to commercialize intellectual property associated with discoveries made during the research project.
CU Licensees Receive Therapeutic Discovery Project Grants
Several CU licensees recently received grants through the Qualifying Therapeutic Discovery Project Program, a program established by last year’s healthcare reform bill. The program is intended to benefit small companies developing technologies that are expected to significantly lower the cost and increase the quality of medical care. Colorado-based CU licensees who received grants: ApopLogic Pharmaceuticals, $108,345; ARCA biopharma, $488,958; BioAMPS International, $83,913; EndoShape, $400,872; GlobeImmune, $733,438; Hiberna Corp., $97,142; ICVrx, $244,479; Inviragen; $488,958; miRagen Therapeutics, $244,479; ProFoldRx (BaroFold), $244,479; Quest Product Development, $244,479; SomaLogic, $1,171,054; and ValveXchange, $244,479. Figures reflect grants for both 2009 and 2010; some (but not all) projects involve CU technologies. (See also: Area Bioscience Firms Cash In on Federal Grants.)
Read the full newsletter, or sign up to receive a monthly email update.
16 hours ago
0 comments:
Post a Comment